2. Search Result
Search Result
Results for "

JAK2-IN-1

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156423
    Tubulin/JAK2-IN-1

    		Microtubule/Tubulin JAK Cancer
    Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .
    Tubulin/JAK2-IN-1
  • HY-109179A
    Itacnosertib (hydrocholide)

    TP-0184 (hydrocholide)

    		 JAK TGF-β Receptor Cancer
    Itacnosertib hydrocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5 .
    Itacnosertib (hydrocholide)
  • HY-109179
    Itacnosertib

    TP-0184

    		 JAK TGF-β Receptor Cancer
    Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871 .
    Itacnosertib
  • HY-10193A
    (1R)-AZD-1480

    		JAK Cancer
    (1R)-AZD-1480 is the (1R) chiral isomer of AZD-1480, an ATP competitive JAK1 and JAK2 inhibitor .
    (1R)-AZD-1480
  • HY-111750
    JAK-IN-3

    		JAK Inflammation/Immunology
    JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .
    JAK-IN-3
  • HY-117810
    JAK2-IN-1

    		JAK Inflammation/Immunology
    JAK2-IN-1 (eExample 2) is a JAK2 inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .
    JAK2-IN-1
  • HY-170393
    iBFAR2

    		JAK STAT Cancer
    iBFAR2, a BFAR inhibitor, restores the CD8+ TRM cell subset against solid tumors. iBFAR2 promotes JAK2-STAT1 association and STAT1 phosphorylation .
    iBFAR2
  • HY-145029
    SYK/JAK-IN-1

    		Syk JAK Inflammation/Immunology Cancer
    SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC50s of <5 nM for SYK and JAK2, respectively .
    SYK/JAK-IN-1
  • HY-W062703S
    (Rac)-Ruxolitinib-d9

    (Rac)-INCB18424-d9; RuxotINib racemate-d9

    		 Isotope-Labeled Compounds JAK Cancer
    (Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .
    (Rac)-Ruxolitinib-d9
  • HY-P1790
    Axltide

    		JAK Metabolic Disease
    Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .
    Axltide
  • HY-154994
    JAK-IN-30

    		JAK Inflammation/Immunology
    JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .
    JAK-IN-30
  • HY-14722A
    NVP-BSK805 dihydrochloride
    3 Publications Verification

    		 JAK Cancer
    NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .
    NVP-BSK805 dihydrochloride
  • HY-14722C
    NVP-BSK805 trihydrochloride

    		JAK Cancer
    NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .
    NVP-BSK805 trihydrochloride
  • HY-14722
    NVP-BSK805
    3 Publications Verification

    		 JAK Cancer
    NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .
    NVP-BSK805
  • HY-162862
    JAK-IN-38

    		JAK Others
    JAK-IN-38 (Compound 1) is a JAK inhibitor, with IC50s of 0.03, 0.06, 0.12, 0.44 μM for Tyk2, JAK3, JAK2, JAK1 respectively. JAK-IN-38 is a collagen VII (C7) inducer and has anti-inflammatory activity. JAK-IN-38 can upregulate the expression of COL7A1 mRNA in donor-derived keratinocytes and works together with Gentamicin (HY-A0276A) to boost overall C7 levels .
    JAK-IN-38
  • HY-13775
    XL019
    5 Publications Verification

    		 JAK Apoptosis Cancer
    XL019?is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .
    XL019
  • HY-155178
    Antiproliferative agent-34

    		EGFR Cancer
    Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC50 of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC50 of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC50 values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC50 values < 10 nM) under hypoxic condition .
    Antiproliferative agent-34

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: